Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01252732 · ClinicalTrials.gov registry record · Phase 3
Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection
A Phase 3 study of Abscess and Cellulitis, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,019
- Enrollment target
- 1
- Study location
NCT01252732 is a Phase 3 study of Abscess and Cellulitis that has completed, run by Melinta Therapeutics. The registered enrollment target is 1,019 participants, above the 312-participant average among 13 other Abscess trials with a reported enrollment target (227% higher). The trial reports 1 study location across 1 state.
The verdict
NCT01252732, a Phase 3 study of Abscess and Cellulitis, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,019 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a single 1200 mg IV dose.
Conditions Studied
Interventions
- DRUG Single-Dose IV Oritavancin Diphosphate
- DRUG IV Vancomycin
Study Locations (1)
California
- Sharp Grossmont Hospital - La Mesa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,019 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01252732
The ClinicalTrials.gov registry entry for NCT01252732 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,019 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 312-participant average among 13 other Abscess trials with a reported enrollment target (227% higher). The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Abscess appearing as the primary indexed condition, and to 2 interventions - of which Single-Dose IV Oritavancin Diphosphate is the first listed.
NCT01252732 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01252732 about?
NCT01252732 is a clinical study titled "Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection". The purpose of this Phase 3 trial is to evaluate the efficacy, safety, and tolerability of oritavancin in ABSSSIs, including those caused by MRSA and to evaluate the potential economic benefit of oritavancin administered as a single 1200 mg IV dose.
What is the current status of trial NCT01252732?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,019 participants. The study started on 2010-12. Estimated completion is 2013-06.
What conditions does trial NCT01252732 study?
This clinical trial studies the following conditions: Abscess, Cellulitis, Wound Infection, Systemic Inflammation.
What interventions are being tested in trial NCT01252732?
The interventions under investigation include: Single-Dose IV Oritavancin Diphosphate (DRUG), IV Vancomycin (DRUG).
Who is sponsoring clinical trial NCT01252732?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01252732 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Abscess
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children
COMPLETED · Phase 3
-
Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
COMPLETED · Phase 3
-
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
COMPLETED · Phase 3
-
Incision and Drainage Versus Needle Aspiration in Soft Tissue Abscesses
COMPLETED · Phase 3
-
Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)
COMPLETED · Phase 3
-
Intranasal Fentanyl as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.